ESR1 and breast carcinoma: A second PROTAC drug, ARV-471 (targeting the estrogen receptor [ER]), is being evaluated in clinical trials for the treatment of patients with locally advanced or metastatic ER+/human epidermal growth factor receptor (HER)2− breast cancer.